Supriya Lifescience Ltd. Company History and Annual Growth Details

The Company was incorporated as ‘Supriya Lifescience Limited’ pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai (“RoC”), upon the conversion of ‘M/s Supriya Chemicals’, a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by the RoC.

Major events and milestones of the Company :

2008

- Incorporation of the Company upon its conversion from a partnership firm to a public limited company

2009

- Started production of Ketamine Hydrochloride

2010

- CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate

2011

- IDL granted for Chlorphenamine Maleate

2013

- COFEPRIS and KFDA approval granted

2014

- USFDA approval granted

- IDL granted for Brompheniramine Maleate

2015

- EUGMP and EDQM approval granted

2017

- CEP (Certificate of Sustainability) granted for Pheniramine Maleate

- Second time USFDA approval granted

2018

- CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride

2020

- Third time USFDA approval

2021

- CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate

- NMPA approval granted

- Health Canada approval

-Supriya Lifescience Limited has informed the Exchange regarding ''Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd''.

2025

-Supriya Lifescience honoured with Maharashtra State Export Award for two consecutive years

-Supriya Lifescience Secures WHO GMP Certification for Ambernath Facility